Multiple companies have made offers for Aurora's business this year, but Tilray hasn't shown any interest.
Announced the launch of the 2 Mile High Whiskey Club, a new membership that delivers limited releases, ...
BRECKENRIDGE, Colo., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, one of the most awarded craft distilleries in the U.S. and a sub...
Earlier this year, the U.S. government announced it would reclassify certain medical cannabis products from Schedule I to Schedule III substances.
Debt and cash flow reveal some significant differences.
Tilray's ambition to move beyond marijuana has hit high gear, and it changes the company's story in a big way.
Tilray commands a 4x revenue advantage, but Canopy's latest quarter hints at momentum—here's what the data reveals about their competitive positioning.
The cannabis stock has generated nearly $1 billion in revenue over the past year, and its market cap is less than half of that.
Tilray's transformation is still ongoing, but it just reached a critical milestone.
Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than the headline suggests. The post This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful appeared first on The Motley Fool Canada.
GlobeNewswire Press Release.
INFARMED approval authorizes Tilray Medical’s Cantanhede, Portugal facility to conduct microbiological and chemical/physical testing on-site, advancing pharmaceutical-grade quality control within its EU-GMP production platformCANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulat
Tilray (TLRY) Q1-2027 results: BrewDog revenue rose, cannabis sales fell, losses and negative FCF persist. Read here for a detailed analysis.
Tilray stock remains a "Hold" as Q1 results miss on revenue as cannabis sales fall, cash burn jumps, and dilution rises. Click to learn more about TLRY.
The company's top line may have increased, but it doesn't take long for investors to spot problems in its recent earnings report.
Motley Fool Press Release.
Tilray Brands (TSX:TLRY) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga
This is the newest page. Registered accounts read further back.